Ratings Navamedic ASA

Equities

NAVA

NO0010205966

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-16 am EDT			5-day change	1st Jan Change
34 ^NOK	+2.72%		+2.72%	-7.36%

May. 06	Navamedic Rolls Out Erectile Dysfunction Drug in Sweden	MT
Apr. 30	Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company is highly valued given the cash flows generated by its activity.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
NAVAMEDIC ASA	-7.36%	55.51M	-
ELI LILLY AND COMPANY	+32.09%	693B	C+
NOVO NORDISK A/S	+29.39%	584B	B
JOHNSON & JOHNSON	-1.34%	372B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+7.39%	294B	C+
ASTRAZENECA PLC	+14.25%	239B	B+
ROCHE HOLDING AG	-3.03%	211B	A+
NOVARTIS AG	+10.02%	210B	B-
AMGEN INC.	+8.49%	168B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes